Copyright
©The Author(s) 2021.
World J Clin Cases. Jun 26, 2021; 9(18): 4690-4699
Published online Jun 26, 2021. doi: 10.12998/wjcc.v9.i18.4690
Published online Jun 26, 2021. doi: 10.12998/wjcc.v9.i18.4690
Table 5 Rates of hepatitis B e antigen loss and hepatitis B e antigen seroconversion in participants with hepatitis B e antigen-positive chronic hepatitis B at week 96
| Group | Number of observations | Number of cases | Incidence | P value | |
| HBeAg loss | A | 100 | 31 | 31.00 | 0.6482 |
| B | 110 | 30 | 27.27 | ||
| HBeAg seroconversion | A | 89 | 18 | 20.22 | 0.4491 |
| B | 95 | 15 | 15.79 |
- Citation: Chen XF, Fan YN, Si CW, Yu YY, Shang J, Yu ZJ, Mao Q, Xie Q, Zhao W, Li J, Gao ZL, Wu SM, Tang H, Cheng J, Chen XY, Zhang WH, Wang H, Xu ZN, Wang L, Dai J, Xu JH. Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks. World J Clin Cases 2021; 9(18): 4690-4699
- URL: https://www.wjgnet.com/2307-8960/full/v9/i18/4690.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i18.4690